A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects

Trial Profile

A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs PTG 300 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 20 Sep 2017 According to a Protagonist Therapeutics media release, the company announced preliminary results from this study.
    • 20 Sep 2017 According to a Protagonist Therapeutics media release, company has amended the study to include two additional cohorts of an 80 mg single dose and a 40 mg dose for two weekly doses. Also planned patient numbers changed from 50 to 62.
    • 25 May 2017 According to a Protagonist Therapeutics media release, the company expects to report results from this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top